Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
MICARDIS HCT 80mg/25mg |
| Manufacturer |
|
Boehringer Ingelheim Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker + diuretic. |
| Generic Name |
|
Telmisartan 80mg, hydrochlorothiazide 25mg; tabs. |
| Also |
• MICARDIS HCT 40mg/12.5mg
• MICARDIS HCT 80mg/12.5mg
|
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Not for initial therapy. May be substituted for titrated components. BP not controlled on telmisartan 80mg/day: one Micardis HCT 80mg/12.5mg tab once daily; may titrate to 160mg/25mg. BP not controlled on HCTZ 25mg/day: one Micardis HCT 80mg/12.5mg tab or 80mg/25mg tab once daily; may titrate to 160mg/25mg if BP uncontrolled after 2–4 weeks. BP controlled on HCTZ 25mg/day but hypokalemic: One Micardis HCT 80mg/12.5mg tab once daily. CrCl ≤30mL/min: not recommended. Hepatic insufficiency or biliary obstruction: initially one Micardis HCT 40mg/12.5mg tab once daily; monitor closely. Severe hepatic impairment: not recommended. |
| Contraindications |
|
Anuria. Sulfonamide allergy. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct hypovolemia before starting, or monitor closely. Renal or hepatic dysfunction. Renal artery stenosis. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Monitor electrolytes. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Digoxin, lithium toxicity. Adjust antidiabetic, antigout medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Orthostatic hypotension potentiated by alcohol, CNS depressants. Antagonized by NSAIDs. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May antagonize pressor amines. |
| Adverse Reactions |
|
Dizziness, GI upset, fatigue, flu-like symptoms, back pain, tachycardia, electrolyte disturbances, orthostatic hypotension, hyperglycemia, hyperuricemia, adverse lipid values, angioedema, rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
